LEARNING OUTCOMES
The student should achieve:
- familiarity with the therapeutic potential of radioisotopes in various malignant diseases
- familiarity with the therapeutic potential of radioisotopes in benign situations.
- knowledge of the technical characteristics of each method- Study of radiation protection
- knowledge of the kinetics of radio pharmaceuticals.
- familiarity with the treatment of pain. – Role of the Radiographer in the support team and monitoring group.
Nuclear Medicine Therapies are types of selective radiotherapy allowing radiation treatment with the least damage to the surrounding normal tissues. The aim of the course is to present students with the most recent types of treatment.
SYLLABUS
1. The role of Ι-131 in the treatment of differentiated thyroid cancer – indications for ablation treatment. Patient preparation – dose – dosimetry–radiation protection after treatment – stunning effect –the role of recombinant TSH [rhTSH] –treatment side effects.
2. Benign thyroid diseases suitable for Ι 131 treatment. Hyperthyroidism, Graves disease, thyroid opthalmopathy, multinodular goiter, autonomous adenomatreatment side effects- dosimetry.
3. Radio hymenolysis – choice of radiopharmaceutical – action mechanism, dosimetry, side effects. The role of Υ-90 Citrate, Erb 169 Citrate, Re 186 Sulfide. Assessment of treatment results.
4. Pain relief. Painful bone matastaseis, pain management, the ideal patient for treatment. Biologic characteristics of the radiopharmaceutical, clinical applications
Sr 89 Chloride, Re 186 HEDP, Sm 153 EDTMP, toxicity, clinical experience, contra indications.
5. Treatment with Ι 131 MIBG, mechanism of uptake, indications, patient selection, patient preparation, care and side effects in pheochromocytoma, neuroblastoma, carcinoid and medullary thyroic cancer.
6. Treatment with somatostatin recepror targeted radiopeptides in the classic NET tumors and hepatocellular cancer. Patient preparation, patient selection, dose, dosimetry.
7. Treatment of malignant collections: intraabdominal, pleural, intracystic, intraarterial
8. Radio immunotherapy and lymphoma. Patient selection criteria, dose, dosimetry, treatment effectiveness, radiation protection.